BSF Enterprise PLC (LON: BSFA) has signed heads of terms with SCHAKAU Managementberatung GmbH for the worldwide exclusive commercialisation of its proprietary bioactive peptide ETSYL® across cosmetics, skincare, dermocosmetics and luxury beauty.
The agreement grants SCHAKAU exclusive global rights for an initial 10-year term, subject to meeting agreed annual volume targets following a 12-month ramp-up period.
SCHAKAU has committed around €300,000 towards market development, including clinical claims, regulatory work, branding and international distribution, while also covering downstream product compliance and efficacy testing costs.
BSF will retain 100% ownership of the intellectual property and will supply ETSYL® through its wholly owned subsidiary 3D Bio-tissues, creating a direct manufacturing revenue stream.
Key Transaction Highlights:
● Exclusive 10-Year Global Term: SCHAKAU receives exclusive worldwide rights in cosmetics and luxury beauty for an initial 10-year period, strictly conditional upon achieving agreed annual commercial volume targets following an initial 12-month ramp-up period.
● Funded Commercialisation: SCHAKAU has allocated a dedicated market development budget estimated at €300,000 to fund clinical claim substantiation, regulatory compliance, brand creation, and international distribution capital.
● Downstream Expenses: SCHAKAU is solely responsible, at its own expense, for all finished consumer product notifications (including CPNP/SCPN portal filings), Cosmetic Product Safety Reports (CPSR), Responsible Person (RP) representations, and clinical efficacy testing.
● Direct Supply Revenue Stream & Expected Timing: BSF will supply compliant bioactive ETSYL® under a structured, dose-based volume schedule, securing commercial manufacturing margins for BSF’s 100% subsidiary, 3D Bio-tissues Ltd. Initial raw material supply revenues are expected during the 12-month product compilation phase ahead of retail launch.
● 50:50 Third-Party Licensing Split: Net licensing income from third-party brand integrations will be split 50:50, after deducting external compliance and international patent prosecution and maintenance costs, directly protecting BSF’s historical and ongoing patent investments.
● 100% IP Retention: BSF retains absolute ownership of all patents, trade secrets, manufacturing know-how, and underlying technology related to ETSYL®.
Net licensing income from third-party cosmetic brand integrations will be split 50:50 between BSF and SCHAKAU after certain external compliance and patent costs.
ETSYL® was originally developed to stimulate cell growth and collagen production in tissue engineering applications, but BSF identified its potential as a high-value active ingredient for premium anti-ageing skincare.
SCHAKAU plans to launch ETSYL® initially through its HANDS OF GOD luxury skincare brand before pursuing wider B2B licensing opportunities with global cosmetics companies.
Chief executive Che Connon said the partnership provides BSF with a capital-light route into the global luxury skincare market while retaining ownership of the underlying technology and generating both supply and licensing revenues.

